Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of acidoglycoprotein ORM in preparing drugs for treating cardiac failure

A technology of acid glycoprotein and heart failure, which is applied in the field of medicine to achieve high safety effects

Active Publication Date: 2018-11-27
SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Currently, there are no reports of acid glycoprotein ORMs having a protective effect on heart failure

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of acidoglycoprotein ORM in preparing drugs for treating cardiac failure
  • Application of acidoglycoprotein ORM in preparing drugs for treating cardiac failure
  • Application of acidoglycoprotein ORM in preparing drugs for treating cardiac failure

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0025] Example 1: Effect of ORM administration on cardiac function in mice with ischemic heart failure

[0026] 1. Method:

[0027] 1. Construction of ischemic heart failure model

[0028] After isoflurane anesthesia, the endotracheal tube was connected to a ventilator to control breathing. Clean surgery was performed under a binocular microscope, and the left fourth intercostal space was opened to expose the left atrial appendage and left ventricle. Under the microscope, the left coronary artery can be seen running downward from the middle of the left atrial appendage edge to the front wall of the left ventricle, and the coronary artery is sutured at a high position about 1mm below the left atrial appendage. After ligation, the myocardium gradually changes from red to pale. ST-segment arched and elevated. The chest was closed layer by layer. After the spontaneous breathing of the mice recovered, the endotracheal tubes were pulled out, caged, fed in a day and night cycle, a...

Embodiment 2

[0033] Example 2: Effect of ORM Administration on Cardiac Function of Isoproterenol-Induced Heart Failure Mice

[0034] 1. Method:

[0035] 1. Construction of isoproterenol drug-induced heart failure mouse model

[0036] Isoproterenol 5 mg / kg / d mice were injected intraperitoneally for 15 days to prepare the isoproterenol-induced heart failure model, and the experiments were carried out after 4 weeks of feeding.

[0037] 2. Cardiac ultrasound

[0038] The method is the same as above.

[0039] 2. Results:

[0040] Such as Figure 2A-Figure 2D As shown, after ORM administration, the ejection fraction EF, short-axis shortening rate FS and stroke volume SV of heart failure mice increased gradually compared with those before administration, and the most significant was at 60 minutes. Cedilan significantly increased EF and FS at 30 minutes, but returned to the level before administration at 60 minutes. * indicates that there is a significant statistical difference compared with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to the technical field of medicines, in particular to an application of acidoglycoprotein ORM in preparing drugs or health-care products for treating cardiac failure. The invention also provides an acidoglycoprotein ORM coding sequence as well as an application of an accelerant of the acidoglycoprotein ORM coding sequence in preparing drugs or health-care products for treating cardiac failure. The invention provides a novel application of acidoglycoprotein ORM in preparing drugs or health-care products for treating cardiac failure. As the acidoglycoprotein ORM is an endogenous protein of a body, the safety of the acidoglycoprotein ORM as a drug is very high.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of acid glycoprotein ORM in the preparation of drugs for treating heart failure. Background technique [0002] The inventors previously discovered an endogenous anti-fatigue protein that increases skeletal muscle endurance: acid glycoprotein Orosomucoid (ORM, α1-Acid Glycoprotein), which is highly expressed in liver, muscle and serum of various fatigue model animals. After ORM knockout, the mice's forced swimming time, isolated skeletal muscle endurance and anti-fatigue index all decreased. ORM can directly improve the contractility and anti-fatigue index of mouse skeletal muscle (reference 1. Lei H, Sun Y, Luo Z, et al. Fatigue-induced Orosomucoid 1Acts on C-C Chemokine Receptor Type 5toEnhance Muscle Endurance. Sci Rep.2016; 6:18839.; 2. Qin Z, Wan JJ, Sun Y, et al. ORM Promotes Skeletal Muscle Glycogen Accumulation via CCR5-Activated AMPK Pathway in Mice. Fro...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/17A61P9/04A23L33/17
CPCA61K38/1735A23L33/17A61P9/04
Inventor 刘霞秦臻孙旸万静静王鹏源张宇苏定冯
Owner SECOND MILITARY MEDICAL UNIV OF THE PEOPLES LIBERATION ARMY